Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 19 July 2018
Indication(s)
Inhixa is indicated in adults for:
• Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
• Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
• Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
• Acute coronary syndrome:
- Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
- Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
Oral Anticoagulation Reversal
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
ESICM LIVES Highlights
ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.
Pain, Agitation and Delirium (PAD) Management
Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.
+ 4 more
Transplantation
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Related Content
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients...
Added 1 year ago
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)
The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death...
Added 7 years ago
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)
In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding...
Added 11 months ago
A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)
This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Added 1 year ago
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...
Added 5 years ago
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Background: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.
Added 1 year ago
Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.
Added 1 year ago
Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.
Aim: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome...
Added 1 year ago
Rivaroxaban in patients with a recent acute coronary syndrome.
Background: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve...
Added 1 year ago
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons...
Added 11 months ago
Prevention and management of venous thromboembolism
The guideline identifies adult patient groups at risk of venous thromboembolism and describes the available methods of prophylaxis, with general recommendations about efficacy, safety, and how they should be used.
Added 8 years ago
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
VTE is a condition in which a blood clot (thrombus) forms in a vein. It most commonly occurs in the...
Added 9 years ago
Guideline on aspects of cancer-related venous thrombosis
This guideline reviews the indication for warfarin, duration or treatment for patients with a PE and/or lower limb DVT, the initiation of treatment, the management of peri-operative anticoagulation, the management of patients who are bleeding or...
Added 3 years ago
Antithrombotics: indications and management
This guideline provides recommendations based on current evidence for best practice in the management of adult patients on antithrombotic therapy.
Added 5 years ago
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
This guideline covers the diagnosis and management of venous thromboembolic diseases in adults (aged 18 and over), and the role of thrombophilia testing.
Added 6 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/004264 |
Orphan designation | No |
Date First Approved | 15-09-2016 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Techdow Europe AB |